Offstream
news

---

Changes

1. The Standing Committee on Vaccination issues a recommendation for approval of the protein-based Novavax COVID-19 vaccine for adults.
   2022-02-04 01:06:06 (First version)
2. The Standing Committee on Vaccination issues a recommendation for the approval of the protein-based Novavax COVID-19 vaccine for use in adults.
   (Current version)

---

Related

The Australian Technical Advisory Group on Immunisation gives the final approval for use of the Novavax COVID-19 vaccine for people over the age of 18 years. The rollout of the vaccine will begin on February 21.
2022-01-24

The Standing Committee on Vaccination recommends that children between the ages of 12 and 17 years should receive a booster dose of the COVID-19 vaccine at least three months after having received their second dose, becoming one of the first countries to authorize booster doses for this age group.
2022-01-13

South Korea authorizes the use of the protein-based Novavax COVID-19 vaccine for adults, making it the fifth vaccine to be approved for use in the country.
2022-01-12

The Standing Committee on Vaccination recommends that a booster dose of an mRNA-based COVID-19 vaccine should be given to all adults over the age of 18 years.
2021-11-18

The Food and Drug Administration of the Philippines authorises emergency use of the Novavax COVID-19 vaccine, which will be included in the national vaccination program.
2021-11-17

The Subject Expert Committee of the Central Drugs Standard Control Organisation will allow the Serum Institute of India to conduct trials of the Novavax COVID-19 vaccine in children between the ages of 7 and 11 years.
2021-09-28

The German Standing Committee on Vaccination recommends that all children between the ages of 12 and 17 receive a COVID-19 vaccine due to increased risks posed by the highly transmissible SARS-CoV-2 Delta variant.
2021-08-16

Denmark confirms that it will purchase 280,000 doses of the Novavax COVID-19 vaccine for a total price of 37 million crowns ($5.84 million) or roughly $20.9 per dose as part of a European Union agreement with Novavax.
2021-08-11

The European Commission signs an agreement with Novavax to purchase 200 million doses of its protein-based COVID-19 vaccines, including an option to purchase another 100 million doses through 2023.
2021-08-4

The German Standing Committee on Vaccination recommends that only children and teenagers with pre-existing illness conditions be given a dose of the Pfizer-BioNTech COVID-19 vaccine due to lack of data on the vaccine's long-term effects.
2021-06-10